Skip to content
10-Q

Quarterly Report

AVEO Pharmaceuticals, Inc.

0001628280-22-012410

← back to feed
Filed
May 5, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · May 2, 2022 34.48M sh
Shares Diluted Q1 2022 · Mar 31, 2022 34.48M sh
Shares Diluted Q1 2022 · Mar 31, 2021 27.43M sh
Operating Cash Flow Q1 2022 · Mar 31, 2022 −$8.22M
Operating Cash Flow Q1 2022 · Mar 31, 2021 −$18.33M
Cash And Equivalents Q1 2022 · Mar 31, 2022 $73.85M
Cash And Equivalents Q1 2022 · Dec 31, 2021 $70.54M
Stockholders Equity Q1 2022 · Mar 31, 2022 $36.94M
Stockholders Equity Q1 2022 · Dec 31, 2021 $45.87M
Stockholders Equity Q1 2022 · Mar 31, 2021 $72.45M
Stockholders Equity Q1 2022 · Dec 31, 2020 $35.29M
Current Liabilities Q1 2022 · Mar 31, 2022 $20.3M
Current Liabilities Q1 2022 · Dec 31, 2021 $18.73M
Total Liabilities Q1 2022 · Mar 31, 2022 $61.27M
Total Liabilities Q1 2022 · Dec 31, 2021 $59.47M
Current Assets Q1 2022 · Mar 31, 2022 $97.73M
Current Assets Q1 2022 · Dec 31, 2021 $104.74M
Total Assets Q1 2022 · Mar 31, 2022 $98.22M
Total Assets Q1 2022 · Dec 31, 2021 $105.34M
Eps Diluted Q1 2022 · Mar 31, 2022 −$0.30
Eps Diluted Q1 2022 · Mar 31, 2021 −$0.81
Eps Basic Q1 2022 · Mar 31, 2022 −$0.30
Eps Basic Q1 2022 · Mar 31, 2021 −$0.81
Sga Expense Q1 2022 · Mar 31, 2022 $17.34M
Sga Expense Q1 2022 · Mar 31, 2021 $15.1M
Rd Expense Q1 2022 · Mar 31, 2022 $10.16M
Rd Expense Q1 2022 · Mar 31, 2021 $5.8M
Net Income Q1 2022 · Mar 31, 2022 −$10.2M
Net Income Q1 2022 · Mar 31, 2021 −$22.12M
Operating Income Q1 2022 · Mar 31, 2022 −$9.01M
Operating Income Q1 2022 · Mar 31, 2021 −$19.12M
Cost Of Revenue Q1 2022 · Mar 31, 2022 $2.43M
Cost Of Revenue Q1 2022 · Mar 31, 2021 $138K
Revenue Q1 2022 · Mar 31, 2022 $20.92M
Revenue Q1 2022 · Mar 31, 2021 $1.92M